Clinical Trial Update: Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning [Phase 2]

View source ↗

Summary

An update on a phase 2 trial evaluating neoadjuvant pembrolizumab in non-metastatic prostate cancer, using 18FDG-PET biomarker guidance.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: CHU de Quebec-Universite Laval | Conditions: Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING